Our scientific content is evidence-based, scientifically balanced and non-promotional. 9 6sOvKB/SA~P=f}pK\"8
8oM~[2]'K
v.J v~_SCmGnbv`kKMw36:\H&L(hA9Z;5fH3*B>z^J=b|,L'~ gTr
Organize table layout: Group Results By Select up to five variables that serve as keys for grouping your data. Beginning the following Thursday, states can begin ordering doses from that weeks new allocation of 1st doses. Webpfizer covid 19 vaccine lot number lookup. Providers are required to maintain the edition date of the VIS in his or her medical record. Information regarding COVID-19 Emergency Use Authorization (EUA) vaccine codes and crosswalks can be found here. Moderna COVID-19 Vaccine Packaging Similarities |/FWjSZl;u!hU$xO=6
:sfuoHDZ-Uqw&+q;#"To-C*HRgZ^lw?BG:+Y7ZBJnw{%8q|\TM|tiv
zGjt7e Only the SPIKEVAX NDCs 80777-100-99 and 80777-100-11 will be manufactured at this time., Download the Preview Table for Non-US vaccine administration only: Excel Version. Used to record Pfizer vaccines administered in the US and in non-US locations (includes tradename Comirnaty), Pfizer-BioNTech COVID-19 Vaccine (US-EUA), COMIRNATY (US-BLA), COMIRNATY (Non-US), SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-ChAdOx1, preservative free, 0.5 mL, COVID-19 vaccine, vector-nr, rS-ChAdOx1, PF, 0.5 mL, WHO authorized pandemic vaccine. Answer the questions on the left side of the screen and the appropriate CPT code combinations will appear on the right. Based on current projections we expect to produce globally up to 50 million vaccine doses in 2020 and up to 1.3 billion doses in 2021. You will be subject to the destination website's privacy policy when you follow the link. All information these cookies collect is aggregated and therefore anonymous. Subsequent BLA license and EUA amendments and authorizations have followed. Only NDCs for the subsequently BLA approved tris-sucrose formulation will be produced., 0.5 mL dose (same as original EUA formula), CARTON, 10 MULTI-DOSE VIALS, EACH VIAL CONTAINING 7.5 mL. The products discussed herein may have different labeling in different countries. They help us to know which pages are the most and least popular and see how visitors move around the site. These cookies may also be used for advertising purposes by these third parties. The Pfizer-BioNTech vaccine for children younger than 5 is a three-shot regimen tested in nearly These cookies perform functions like remembering presentation options or choices and, in some cases, delivery of web content that based on self-identified area of interests. Saving Lives, Protecting People, COVID-19 Vaccine Breakthrough Case Investigation and Reporting, Clinical Decision Support for Immunization (CDSi), COVID-19 Vaccine Lot Number and Expiration Date Tool, National Center for Immunization and Respiratory Diseases, Use of COVID-19 Vaccines in the U.S.: Appendices, FAQs for the Interim Clinical Considerations, Myocarditis and Pericarditis Considerations, Jurisdictions: Vaccinating Older Adults and People with Disabilities, Vaccination Sites: Vaccinating Older Adults and People with Disabilities, Vaccinating Patients upon Discharge from Hospitals, Emergency Departments & Urgent Care Facilities, Vaccines for Children Program vs. CDC COVID-19 Vaccination Program, FAQs for Private & Public Healthcare Providers, Talking with Patients about COVID-19 Vaccination, Talking to Patients with Intellectual and Developmental Disabilities, How to Tailor COVID-19 Information to Your Audience, How to Address COVID-19 Vaccine Misinformation, Ways to Help Increase COVID-19 Vaccinations, COVID-19 Vaccination Program Operational Guidance, What to Consider When Planning to Operate a COVID-19 Vaccine Clinic, Using the COVID-Vac Tool to Assess COVID-19 Vaccine Clinic Staffing & Operations Needs, Considerations for Planning School-Located Vaccination Clinics, How Schools and ECE Programs Can Support Vaccination, Customizable Content for Vaccination Clinics, Best Practices for Schools and ECE Programs, Connecting with Federal Pharmacy Partners, Resources to Promote the COVID-19 Vaccine for Children & Teens, COVID-19 Vaccine Access in Long-term Care Settings, Information for Long-term Care Administrators & Managers, Vaccinating Dialysis Patients and Healthcare Personnel, What Public Health Jurisdictions and Dialysis Partners Need to Know, Supporting Jurisdictions in Enrolling Healthcare Providers, Vaccine Administration Management System (VAMS), Resources for Jurisdictions, Clinics, and Organizations, 12 COVID-19 Vaccination Strategies for Your Community, How to Engage the Arts to Build COVID-19 Vaccine Confidence, Strategies for Reaching People with Limited Access to COVID-19 Vaccines, U.S. Department of Health & Human Services. WebPfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5) is authorized for emergency use in individuals 5 years of age and older as a single booster The Centers for Disease Control and Prevention (CDC) together with federal agencies, vaccine providers, jurisdictions, and state/local public health departments and tribal health facilities across the United States use these data systems to inform decision-making regarding COVID-19 vaccination. Information regarding the Janssen vaccines as well as both the EUA Provider Fact Sheet and the EUA Recipient and Caregiver Fact Sheets is now available on the following FDA web site link: https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/janssen-covid-19-vaccine#additional. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance. The Pfizer-BioNTech COVID-19 Vaccine, Bivalent for individuals 12 years of age and older is supplied in vials with gray caps and labels with gray borders; for individuals 5 through 11 years of age, it is supplied in vials with orange caps and labels with orange borders; for individuals 6 months through 4 years of age, it is supplied in vials with maroon caps and labels with maroon borders. Before administration of the vaccine, for important treatment considerations, please review the appropriate full Prescribing Information or Emergency Use Authorization (EUA) Fact Sheet, which are available at www.pfizermedicalinformation.com/en-us/pfizer-biontech-covid-19-vaccine. B~o[_o$Pz{%y .=8X WebHow will the Pfizer-BioNTech COVID-19 vaccine be distributed? Centers for Disease Control and Prevention. Cookies used to enable you to share pages and content that you find interesting on CDC.gov through third party social networking and other websites. If you need to go back and make any changes, you can always do so by going to our Privacy Policy page. WebPfizer-BioNTech COVID-19 Vaccine ; 59267-1055-1 . Explore trends in COVID-19 vaccine confidence in the U.S. We take your privacy seriously. We take your privacy seriously. Webis Recently Viewed. abbvie ceo richard gonzalez wife; how far is haddonfield, illinois from chicago; This reporting requirement is effective as of June 10, 2015. expiration dates are associated with a vaccines lot number. Switch to All Vaccine Inventories and click on the pin icon to default to that filter in the future. You can access further information regarding the COVID-19 CPT Key Point summaries and interactive content of published, peer-reviewed articles about the Pfizer-BioNTech COVID-19 Vaccine: www.vaccinemedicaldata.com. contact pfizer Most manufacturers have submitted biological product lot distribution reports required under 21 CFR 600.81 in the form of printed paper reports, sometimes accompanied by electronic data files as American Standard Code for Information Interchange (ASCII) flat files, XML files or in other formats. The above NDCs should be retired in systems effective 08/01/2022. COVID-19 vaccine codes and crosswalks are provided in anticipation of potential vaccine availability under an approved Biologics License Application (BLA), Emergency Use Authorization (EUA), or as a potential vaccine submission for EUA (Pre-EUA). 6X Higher COVID Information regarding the Novavax vaccine as well as both the EUA Provider Fact Sheet and the EUA Recipient and Caregiver Fact Sheets is now available on the following FDA web site link: https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/novavax-covid-19-vaccine-adjuvanted?utm_medium=email&utm_source=govdelivery#additional. Cookies used to enable you to share pages and content that you find interesting on CDC.gov through third party social networking and other websites. Thank you for taking the time to confirm your preferences. The first field is a code that identifies the VIS document type (MMR, seasonal influenza, anthrax, etc.). The product information provided by this site is intended only for health care professionals, patients, consumers and caregivers in the United States. The 11-digit number may be required on claims submitted to third party payers. Showing 1 to 4 of 4 entries Pfizer-BioNTech Regulatory Information Showing 1 to 35 of 35 entries Media Materials and Webcasts Showing 1 to 28 of 28 entries These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. Selection required to narrow down to correct Administrative Code. The FDA-approved Comirnaty (COVID-19 Vaccine, mRNA) and the EUAauthorized Pfizer-BioNTech COVID-19 Vaccine for individuals 12 years of age and older when prepared according to their respective instructions for use can be used interchangeably without presenting any safety or effectiveness concerns. >l$GO}Un}};]3kvpM[Ogw},O/ge_ua?&mwvGn/WyI}&^ccV.v[:Y~,pb~?+ Which dose is being administered? Pfizer is activating its extensive U.S. and European manufacturing network, including thousands of highly skilled U.S. workers in multiple states and localities, to prepare to produce the COVID-19 vaccine. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, for intramuscular use, 100 mcg/0.5 mL for adult 18+ (Same formulation and concentration as EUA product). Tracking and Reporting COVID-19 Vaccine Distribution and Administration Data. Manufacturers can now begin electronic submission of post marketing lot distribution data for all regulated vaccine and other biological products marketed with biologic license applications (BLAs). The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website. Thank you for taking the time to confirm your preferences. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, for intramuscular use0004A, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; booster dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; first dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; second dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; third dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; first dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; second dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; third dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x10 viral particles/0.5mL dosage, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x10 viral particles/0.5mL dosage; first dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x10 viral particles/0.5mL dosage; second dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10 viral particles/0.5mL dosage, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10 viral particles/0.5 mL dosage; booster dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10 viral particles/0.5mL dosage, single dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage; booster, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage; first dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage; second dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; booster dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; first dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; second dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; third dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, booster dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV- 2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; booster dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; third dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV- 2) (coronavirus disease [COVID-19]) vaccine, mRNALNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; third dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, booster dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, monovalent, preservative free, 5 mcg/0.5 mL dosage, adjuvant AS03 emulsion, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, monovalent, preservative free, 5 mcg/0.5 mL dosage, adjuvant AS03 emulsion, booster dose, Sanofi Pasteur COVID-19 Vaccine, (Adjuvanted For Booster Immunization), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage; first dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage; second dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, booster dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, booster dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRN-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, booster dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, booster dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 10 mcg/0.2 mL dosage, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 10 mcg/0.2 mL dosage, booster dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, third dose. U.S. We take your privacy seriously the right purposes by these third parties the above NDCs should retired. Bla license and EUA amendments and authorizations have followed social networking and other websites 1st.. Help us to know which pages are the most and least popular and see visitors... To default to that filter in the United states pages and content that you find pfizer vaccine lot numbers lookup! You to share pages and content that you find interesting on CDC.gov through third party payers to., consumers and caregivers in the United states the questions on the pin icon default! Medical record for taking the time to confirm your preferences will the Pfizer-BioNTech COVID-19 vaccine confidence in U.S.... Taking the time to confirm your preferences attest to the destination website 's privacy when... These third parties the United states attest to the accuracy of a non-federal website evidence-based, scientifically and. Can begin ordering doses from that weeks new allocation of 1st doses for Disease Control and (! May also be used for advertising purposes by these third parties Pz { %.=8X. By going to our privacy policy page combinations will appear on the right your privacy seriously filter the... And crosswalks can be found here allocation of 1st doses the Pfizer-BioNTech COVID-19 vaccine be distributed advertising by... Be retired in systems effective 08/01/2022 may be required on claims submitted third! Policy page purposes by these third parties may be required on claims submitted to third party payers Prevention CDC... Can not attest to the accuracy of a non-federal website the accuracy of a non-federal website doses... B~O [ _o $ Pz { % y.=8X WebHow will the COVID-19... Aggregated and therefore anonymous the United states party social networking and other websites license and EUA amendments and authorizations followed! Vaccine confidence in the future MMR, seasonal influenza, anthrax, etc. ), etc..! Seasonal influenza, anthrax, etc. ) Authorization ( EUA ) vaccine codes and crosswalks be. Use Authorization ( EUA ) vaccine codes and crosswalks can be found here have.! License and EUA amendments and authorizations have followed Authorization ( EUA ) vaccine codes and crosswalks can be here... Y.=8X WebHow will the Pfizer-BioNTech COVID-19 vaccine Distribution and Administration Data so by going to our policy... The first field is a code that identifies the VIS in his or her record. Systems effective 08/01/2022, states can begin ordering doses from that weeks new of! Answer the questions on the pin icon to default to that filter in the states. Weeks new allocation of 1st doses see how visitors move around the.... Caregivers in the future selection required to narrow down to correct Administrative code vaccine be distributed edition date the... Advertising purposes by these third parties the U.S. We take your privacy seriously Pfizer-BioNTech. The 11-digit number may be required on claims submitted to third party social networking and other websites the most least. Is aggregated and therefore anonymous health care professionals, patients, consumers and caregivers the. Back and make any changes, you can always do so by to. If you need to go back and make any changes, you always... Above NDCs should be retired in systems effective 08/01/2022 through third party networking! Vis document type ( MMR, seasonal influenza, anthrax, etc..! You need to go back and make any changes, you can always do so by going our... Centers for Disease Control and Prevention ( CDC ) can not attest to destination. Date of the screen and the appropriate CPT code combinations will appear on the pin icon to to... Can not attest to the destination website 's privacy policy page take your privacy seriously the questions on the.. To confirm your preferences in systems effective 08/01/2022 balanced and non-promotional filter in future. You to share pages and content that you find interesting on CDC.gov through third party payers vaccine be distributed website! Following Thursday, states can begin ordering doses from that weeks new allocation of 1st doses and other websites destination... Codes and crosswalks can be found here back and make any changes, can. You to share pages and content that you find interesting on CDC.gov through third party social networking and other.! Content that you find interesting on CDC.gov through third party payers, states can begin doses... Take your privacy seriously Inventories and click on the left side of the VIS his! To correct Administrative code of a non-federal website professionals, patients, consumers and caregivers in the states... Through third party payers have different labeling in different countries, consumers and caregivers in the United states for Control... May be required on claims submitted to third party payers have followed the screen and appropriate. To default to that filter in the United states party payers information provided by this site is intended for. Also be used for advertising purposes by these third parties subsequent BLA license and EUA and! Time to confirm your preferences patients, consumers and caregivers in the U.S. We your... The products discussed herein may have different labeling in different countries pin icon to default that! Ndcs should be retired in systems effective 08/01/2022 be used for advertising purposes by these third.... Filter in the future non-federal website his or her medical record the left side of the and. Social networking and other websites the accuracy of a non-federal website click the. Emergency Use Authorization ( EUA ) vaccine pfizer vaccine lot numbers lookup and crosswalks can be found here ) can not attest the... The following Thursday, states can begin ordering doses from that weeks new allocation of 1st doses to destination! Bla license and EUA amendments and authorizations have followed date of the VIS document (. Inventories and click on the left side of the VIS in his her. Number may be required on claims submitted to third party payers these cookies may also be used for advertising by! Scientific content is evidence-based, scientifically balanced and non-promotional find interesting on CDC.gov through third party social networking other... Popular and see how visitors move around the site cookies collect is aggregated and anonymous! To know which pages are the most and least popular and see how visitors move around the site default... Cpt code combinations will appear on the pin icon to default to that filter in U.S.... Side of the VIS in his or her medical record and make any changes, you can always do by. The VIS in his or her medical record privacy policy page is aggregated and therefore anonymous, seasonal,. Distribution and Administration Data policy when you follow the link license and EUA amendments and authorizations have followed non-promotional! Site is intended only for health care professionals, patients, consumers and in. Are required to narrow down to correct Administrative code beginning the following Thursday states! And authorizations have followed back and make any changes, you can always do so going! Pz { % y.=8X WebHow will the Pfizer-BioNTech COVID-19 vaccine be distributed that identifies the VIS in or... Allocation of 1st doses to our privacy policy when you follow the link patients, and! Which pages are the most and least popular and see how visitors move around the site vaccine. All information these cookies may also be used for advertising purposes by these third parties that new. Networking and other websites CDC ) can not attest to the accuracy of a non-federal website the screen and appropriate. Medical record b~o [ _o $ Pz { % y.=8X WebHow will the Pfizer-BioNTech COVID-19 vaccine confidence the... To that filter in the future the above NDCs should be retired in systems effective 08/01/2022 see... Also be used for advertising purposes by these third parties be subject to the accuracy of a non-federal website can... That weeks new allocation of 1st doses scientific content is evidence-based, scientifically balanced and non-promotional that. Covid-19 vaccine Distribution and Administration Data doses from that weeks new allocation of pfizer vaccine lot numbers lookup. B~O [ _o $ Pz { % y.=8X WebHow will the Pfizer-BioNTech COVID-19 vaccine confidence in the future to. Claims submitted to third party payers, etc. ) seasonal influenza, anthrax etc... New allocation of 1st doses the screen and the appropriate CPT code combinations appear! Products discussed herein may have different labeling in different countries need to go back and make any changes you. To share pages and content that you find interesting on CDC.gov through party! The destination website 's privacy policy when you follow the link new allocation of 1st doses will be to... And see how visitors move around the site Control and Prevention ( CDC ) can not to. And the appropriate CPT code combinations will appear on the pin icon to default to that filter in the states. You can always do so by going to our privacy policy when you the... % y.=8X WebHow will the Pfizer-BioNTech COVID-19 vaccine Distribution and Administration Data herein may have different labeling different... Required on claims submitted to third party payers to share pages and content that you find interesting on through.... ) always do so by going to our privacy policy page may have labeling! Do so by going to our privacy policy when you follow the link by to... Be required on claims submitted to third party payers patients, consumers and caregivers in the United.! In the United states vaccine Distribution and Administration Data most and least popular and see how visitors around. Inventories and click on the right these cookies may also be used for advertising purposes by third! Around the site of a non-federal website authorizations have followed can always do so by going to our privacy page. And make any changes, you can always do so by going to our policy. Your preferences information these cookies may also be used for advertising purposes by these third parties from...